Pharmaceutical Technology Europe - March 2012 - (Page 2)
SPECIAL FEATURE
Optimising adjuvant
filtration
Adjuvants are increasingly being used to boost
therapeutic response in vaccines and other drug
formulations. Some of these substances, however, are
close enough in size to bacteria that they are unable
to pass through sterilising-grade filters. Others have
low surface tension that can reduce a filter’s bacterial
retention. We spoke to several industry experts to gain
insight on resolving these technical challenges.
Our expert roundtable considers the following questions:
How can pharmaceutical or filter manufacturers reduce
filter plugging or pore blockage?
Low surface tension of some adjuvant solutions can
reduce the efficiency of filters’ bacterial retention. How
can this problem be mitigated?
Read the full responses at
PharmTech.com/adjuvant
2 SPECIAL FEATURE
11 PARAMETRIC RELEASE
Q1. Bromm: One
possibility for filter
manufacturers to deal
with these challenges
is to develop sterilisinggrade
filters that
specifically address these
needs. According to
our experience, highly
asymmetric membranes,
such as polyethersulfone
(PES) membranes provide
a higher flow rate
and capacity for such
types of formulations
compared with symmetric
membranes. According to
practical experiences, the
use of a heterogeneous
double-layer membrane
construction provides
7 REDUNDANT FILTRATION
12 COLUMN CRUNCH
8 NEWS BITES
13 PEER REVIEW
9 BLOG
14 TOP TECH
http://www.PharmTech.com/adjuvant
Table of Contents for the Digital Edition of Pharmaceutical Technology Europe - March 2012